{"id":"gr1803","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GR1803 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoint targets, the drug aims to synergistically enhance T cell activation and proliferation while reducing immunosuppressive signals in the tumor microenvironment.","oneSentence":"GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:25.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT07348055","phase":"PHASE1, PHASE2","title":"A Study of GR1803 in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-02-02","conditions":"Systemic Lupus Erthematosus, Auto Immune Disease","enrollment":44},{"nctId":"NCT07102706","phase":"PHASE1, PHASE2","title":"Phase I Trial of GR1803 Injection in Patients With RRMM","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-05-27","conditions":"Multiple Myeloma (MM)","enrollment":76},{"nctId":"NCT07090954","phase":"PHASE1, PHASE2","title":"A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2025-08-31","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT06952075","phase":"PHASE2","title":"GR1803 Injection in Patients With RRMM","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2025-04-24","conditions":"Multiple Myleoma","enrollment":30},{"nctId":"NCT06566547","phase":"PHASE2","title":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2024-08-26","conditions":"Multiple Myeloma","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GR1803","genericName":"GR1803","companyName":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","companyId":"genrix-shanghai-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}